AU775140B2 - Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response - Google Patents

Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response Download PDF

Info

Publication number
AU775140B2
AU775140B2 AU38806/00A AU3880600A AU775140B2 AU 775140 B2 AU775140 B2 AU 775140B2 AU 38806/00 A AU38806/00 A AU 38806/00A AU 3880600 A AU3880600 A AU 3880600A AU 775140 B2 AU775140 B2 AU 775140B2
Authority
AU
Australia
Prior art keywords
carbon atoms
inclusive
branched
straight chain
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU38806/00A
Other languages
English (en)
Other versions
AU3880600A (en
Inventor
Charles N. Serhan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Brigham and Womens Hospital Inc
Original Assignee
Brigham and Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham and Womens Hospital Inc filed Critical Brigham and Womens Hospital Inc
Publication of AU3880600A publication Critical patent/AU3880600A/en
Application granted granted Critical
Publication of AU775140B2 publication Critical patent/AU775140B2/en
Priority to AU2004222825A priority Critical patent/AU2004222825B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Cephalosporin Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU38806/00A 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response Ceased AU775140B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2004222825A AU2004222825B2 (en) 1999-03-18 2004-10-22 Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12520599P 1999-03-18 1999-03-18
US60/125205 1999-03-18
PCT/US2000/006582 WO2000054767A1 (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of tnf-(alfa) initiated neutrophil response

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2004222825A Division AU2004222825B2 (en) 1999-03-18 2004-10-22 Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response

Publications (2)

Publication Number Publication Date
AU3880600A AU3880600A (en) 2000-10-04
AU775140B2 true AU775140B2 (en) 2004-07-22

Family

ID=22418647

Family Applications (1)

Application Number Title Priority Date Filing Date
AU38806/00A Ceased AU775140B2 (en) 1999-03-18 2000-03-14 Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response

Country Status (11)

Country Link
US (6) US6387953B1 (enExample)
EP (1) EP1165066B1 (enExample)
JP (1) JP4440481B2 (enExample)
AT (1) ATE310512T1 (enExample)
AU (1) AU775140B2 (enExample)
CA (3) CA2615917C (enExample)
DE (1) DE60024242T2 (enExample)
DK (1) DK1165066T3 (enExample)
ES (1) ES2249257T3 (enExample)
HK (1) HK1043307B (enExample)
WO (1) WO2000054767A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650435A (en) 1991-04-01 1997-07-22 Madara; James L. Modulation of inflammation related to columnar epithelia
US6387953B1 (en) * 1999-03-18 2002-05-14 Brigham And Women's Hopsital Inhibition of TNF-(α)-initiated neutrophil response
ES2344138T3 (es) 1999-03-18 2010-08-19 The Brigham And Women's Hospital, Inc. Analogos de 16-fenoxi-lipoxina para utilizacion medica.
ATE303355T1 (de) * 1999-03-18 2005-09-15 Brigham & Womens Hospital Lipoxinverbindungen und ihre anwendung
ATE344226T1 (de) 2000-02-16 2006-11-15 Brigham & Womens Hospital Aspirin-ausgelöste lipidmediatoren
WO2001070664A2 (en) * 2000-03-20 2001-09-27 Trustees Of Boston University Lipoxin analogs and methods for the treatment of periodontal disease
GB2362140B (en) * 2000-05-12 2003-03-05 Autoliv Dev Improvements in or relating to an apparatus for a method of folding an air-bag
PT1406698E (pt) * 2001-03-02 2009-01-12 Brigham & Womens Hospital Análogos de lipoxina como novos inibidores da angiogénese
US8722654B2 (en) 2001-03-02 2014-05-13 The Brigham And Women's Hospital, Inc. Lipoxin analogs as novel inhibitors of angiogenesis
CA2465117C (en) * 2001-11-06 2012-01-03 Brigham And Women's Hospital, Inc. Lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US6831186B2 (en) * 2001-11-06 2004-12-14 Schering Aktiengesellschft Lipoxin A4 analogs
EP1911448B1 (en) * 2001-11-06 2013-01-02 The Brigham and Women's Hospital, Inc. Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US20030195248A1 (en) 2001-12-18 2003-10-16 Serhan Charles N. Novel approach to anti-microbial host defense with molecular shields with lipoxin compounds
US8481772B2 (en) 2002-04-01 2013-07-09 University Of Southern California Trihydroxy polyunsaturated eicosanoid derivatives
US7902257B2 (en) 2002-04-01 2011-03-08 University Of Southern California Trihydroxy polyunsaturated eicosanoid
EP2216318B1 (en) * 2002-08-12 2018-10-10 Brigham And Women's Hospital Resolvins: Biotemplates for therapeutic interventions
US7759395B2 (en) * 2002-08-12 2010-07-20 The Brigham And Women's Hospital, Inc. Use of docosatrienes, resolvins and their stable analogs in the treatment of airway diseases and asthma
WO2004078143A2 (en) * 2003-03-05 2004-09-16 The Brigham And Women's Hospital Inc. Methods for identification and uses of anti-inflammatory receptors for eicosapentaenoic acid analogs
CN1946734B (zh) * 2004-02-26 2012-07-18 贝勒研究院 系统性治疗关节炎的组合物和方法
WO2005105025A1 (en) * 2004-04-14 2005-11-10 Boston University Methods and compositions for preventing or treating periodontal diseases
WO2007041440A2 (en) 2005-10-03 2007-04-12 The Brigham And Women's Hospital, Inc. Anti-inflammatory actions of neuroprotectin d1/protectin d1 and its natural stereoisomers
WO2007061783A1 (en) * 2005-11-18 2007-05-31 Trustees Of Boston University Treatment and prevention of bone loss using resolvins
US7906678B2 (en) 2006-12-04 2011-03-15 Bayer Schering Pharma Aktiengesellschaft Crystalline potassium salt of lipoxin A4 analogs
WO2011050126A1 (en) * 2009-10-21 2011-04-28 University Of Medicine And Dentistry Of New Jersey Method for treating sepsis or septic shock
EP3576843A4 (en) 2017-01-31 2020-11-11 The Brigham and Women's Hospital, Inc. ALX RECEIVER LIGANDS DEFINING A BIOCHEMICAL ENDOTYPE FOR INFLAMMATION-BASED DISEASES
CA3114750A1 (en) 2018-10-09 2020-04-16 University Of Rochester Treatment of vulvovaginal disorders

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5441951A (en) * 1994-06-15 1995-08-15 Brigham & Women's Hospital Lipoxin compounds
US6048897A (en) * 1993-06-15 2000-04-11 Brigham And Women's Hospital Lipoxin compounds and their use in treating cell proliferative disorders
CA2164951C (en) 1993-06-15 2004-02-10 Charles N. Serhan Lipoxin compounds
WO1995001179A1 (en) * 1993-06-29 1995-01-12 Brigham & Women's Hospital Modulation of inflammation related to columnar epithelia
ES2344138T3 (es) * 1999-03-18 2010-08-19 The Brigham And Women's Hospital, Inc. Analogos de 16-fenoxi-lipoxina para utilizacion medica.
US6387953B1 (en) * 1999-03-18 2002-05-14 Brigham And Women's Hopsital Inhibition of TNF-(α)-initiated neutrophil response
ATE303355T1 (de) * 1999-03-18 2005-09-15 Brigham & Womens Hospital Lipoxinverbindungen und ihre anwendung

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SEE REFERENCES OF WO 2000/054767 *

Also Published As

Publication number Publication date
CA2367909A1 (en) 2000-09-21
US6703423B2 (en) 2004-03-09
HK1043307A1 (en) 2002-09-13
DE60024242T2 (de) 2006-12-14
CA2615917C (en) 2011-10-04
DE60024242D1 (de) 2005-12-29
EP1165066A1 (en) 2002-01-02
CA2367909C (en) 2008-02-12
US20080312323A1 (en) 2008-12-18
US6387953B1 (en) 2002-05-14
CA2747376A1 (en) 2000-09-21
US20020132847A1 (en) 2002-09-19
HK1043307B (en) 2006-02-03
US20040192785A1 (en) 2004-09-30
ES2249257T3 (es) 2006-04-01
CA2615917A1 (en) 2000-09-21
WO2000054767A1 (en) 2000-09-21
JP4440481B2 (ja) 2010-03-24
EP1165066B1 (en) 2005-11-23
JP2002539159A (ja) 2002-11-19
ATE310512T1 (de) 2005-12-15
US20020143069A1 (en) 2002-10-03
DK1165066T3 (da) 2006-03-06
US7132451B2 (en) 2006-11-07
US20080081838A1 (en) 2008-04-03
US6710084B2 (en) 2004-03-23
AU3880600A (en) 2000-10-04

Similar Documents

Publication Publication Date Title
AU775140B2 (en) Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
AU2008216965B2 (en) Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
US7994219B2 (en) Approach to anti-microbial host defense with molecular shields with lipoxin compounds
JP2002539181A (ja) リポキシン化合物およびこれらの使用
AU2004222825B2 (en) Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
AU2007214312B2 (en) Use of lipoxin compounds for inhibiting of TNF-(alfa) initiated neutrophil response
EP1616566A1 (en) Lipoxin compounds for treating TNF-alpha initiated inflammation
HK1078497A (en) Lipoxin compounds for treating tnf-alpha initiated inflammation
EP1911448B1 (en) Lipoxins and Aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases
AU2012203640A1 (en) Lipoxins and Asprin-Triggered Lipoxins and their Stable Analogs in the Treatment of Asthma and Inflammatory Airway Diseases
AU2002352553A1 (en) Lipoxins and aspirin-triggered lipoxins and their stable analogs in the treatment of asthma and inflammatory airway diseases